✦ LIBER ✦

Taps to Alzheimer's patients: A continuous Japanese study of cerebrospinal fluid biomarkers

✍ Scribed by Mikio Shoji; Mitsuyasu Kanai; Etsuro Matsubara; Masaki Ikeda; Yasuo Harigaya; Koichi Okamoto; Shunsaku Hirai

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 154 KB
Volume: 48
Category: Article
ISSN: 0364-5134
DOI: 10.1002/1531-8249(200009)48:3<402::aid-ana23>3.0.co;2-g

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

To tap or not to tap: Cerebrospinal flui

To tap or not to tap: Cerebrospinal fluid biomarkers of Alzheimer's disease

✍ John H. Growdon 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

The selective muscarinic M1 agonist AF10

The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease

✍ Roger M. Nitsch; Meihua Deng; Marsha Tennis; David Schoenfeld; John H. Growdon 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre